← Back to Search
Application Potential Of Engineered Liposomes In Tumor Targeting
Ankit Jain, S. Jain
Published 2017 · Chemistry
Download PDFAnalyze on Scholarcy
Most anticancer agents are poorly water soluble and highly potent by nature, leading to nonselective devastation of tumor, as well as normal healthy cells; this poses an obstinate challenge in safe and effective tumor chemotherapy. To get the better of this debilitating problem, liposomes have emerged as revolutionary cargoes, in last few decades, with successful rates on the rise in tumor targeting. Their extraordinary capability to carry both hydrophilic and hydrophobic bioactives in separate domains of residence and amenability to surface and compositional engineering destine this vesicular system to come true the “magic bullet concept” which was enunciated by the great biologist Paul Ehrlich. Enhanced permeability and retention effect and tumor specific ligands mediate passive targeting and active targeting to tumors, respectively. The stealth effect attributed to PEGylation in liposomes has opened up new horizons in prolonged drug delivery, and proved to be a promising tactic to solve safety issues associated with active targeting principles. Current scenarios in liposomes fabrication techniques bring forth environmentally responsive features (pH, temperature, and photosensitivity, etc.) to facilitate enhanced localization at the tumor site, in addition to targeting capabilities. This chapter sums up the drug targeting potential of the engineered liposomes, with contemporary trends in the field of liposomal research.
This paper references
Polyethylene glycol (PEG) modified 99mTc-HMPAO-liposome for improving blood circulation and biodistribution: the effect of the extent of PEGylation.
Changmoon Lee (2005)
Colon Targeted Liposomal Systems (CTLS): Theranostic Potential.
A. Jain (2015)
Liposomal Tumor Targeting in Drug Delivery Utilizing MMP-2- and MMP-9-Binding Ligands
Oula Penate Medina (2011)
Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv.
Kristin S. Loomis (2010)
POLY(HPMA)-COATED LIPOSOMES DEMONSTRATE PROLONGED CIRCULATION IN MICE
K. Whiteman (2001)
Targeted BikDD Expression Kills Androgen-Dependent and Castration-Resistant Prostate Cancer Cells
X. Xie (2014)
Stimuli-responsive liposome fusion mediated by gold nanoparticles.
Dissaya Pornpattananangkul (2010)
Liposomes and inorganic nanoparticles for drug delivery and cancer imaging.
C. Heneweer (2012)
Novel multifunctional theranostic liposome drug delivery system: construction, characterization, and multimodality MR, near-infrared fluorescent, and nuclear imaging.
S. Li (2012)
The radiobiological principles of boron neutron capture therapy: a critical review.
J. Hopewell (2011)
'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption.
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients
N. M. La-Beck (2011)
Selection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines.
D. Bedi (2014)
Absolute MR thermometry using nanocarriers.
Roel Deckers (2014)
Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
X. Chen (2010)
Multi-functional liposomes having temperature-triggered release and magnetic resonance imaging for tumor-specific chemotherapy.
K. Kono (2011)
Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA.
Federico Perche (2011)
Antitumor Effect of Paclitaxel-Loaded PEGylated Immunoliposomes Against Human Breast Cancer Cells
T. Yang (2007)
Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times.
G. Blume (1993)
Topotecan Liposomes: A Visit from a Molecular to a Therapeutic Platform.
Shivani Saraf (2016)
Tumor Metastasis: Molecular Insights and Evolving Paradigms
Scott Valastyan (2011)
A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma
Wen-bing Dai (2015)
The anti-tumoral efficacy of a docetaxel-loaded liposomal drug delivery system modified with transferrin for ovarian cancer.
M. Yuan (2014)
Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model.
Man-Yi Wong (2011)
Methylation of the phosphate oxygen moiety of phospholipid‐methoxy(polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin production
S. Moein Moghimi (2006)
An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin
A. Gabizon (2007)
Photodynamic therapy of cancer: An update
P. Agostinis (2011)
Distearoylphosphatidylethanolamine-based liposomes for ultrasound-mediated drug delivery.
T. J. Evjen (2010)
Dose Dependency of Pharmacokinetics and Therapeutic Efficacy of Pegylated Liposomal Doxorubicin (DOXIL) in Murine Models
A. Gabizon (2002)
Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy.
K. Takara (2012)
Liposome clearance in mice: the effect of a separate and combined presence of surface charge and polymer coating.
T. Levchenko (2002)
Lactobionic acid coupled liposomes: an innovative strategy for targeting hepatocellular carcinoma
Divya Bansal (2016)
An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells.
Mst. Naznin Ara (2014)
Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer
Ankit Jain (2016)
Targeted drug delivery to tumors: myths, reality and possibility.
Y. Bae (2011)
Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer.
Wenbing Dai (2014)
Liposomes co-modified with cholesterol anchored cleavable PEG and octaarginines for tumor targeted drug delivery
J. Tang (2014)
Red-cell ICAM-4 is a ligand for the monocyte/macrophage integrin CD11c/CD18: characterization of the binding sites on ICAM-4.
E. Ihanus (2007)
Highly temperature-sensitive liposomes based on a thermosensitive block copolymer for tumor-specific chemotherapy.
K. Kono (2010)
Targeting efficiency of RGD-modified nanocarriers with different ligand intervals in response to integrin αvβ3 clustering.
Zhaoming Guo (2014)
Penetrating the cell membrane, thermal targeting and novel anticancer drugs: the development of thermally targeted, elastin-like polypeptide cancer therapeutics.
Jung Su Ryu (2014)
Improved in vivo delivery of m-THPC via pegylated liposomes for use in photodynamic therapy.
M. Bovis (2012)
Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors.
R. Campbell (2002)
Cationic Liposomal Co-delivery of Small Interfering RNA and a MEK Inhibitor for Enhanced Anticancer Efficacy
S. H. Kang (2011)
Computed Tomography Imaging of Transferrin Targeting Liposomes Encapsulating Both Boron and Iodine Contrast Agents by Convection-Enhanced Delivery to F98 Rat Glioma for Boron Neutron Capture Therapy
S. Miyata (2011)
Constrained and UV-activatable cell-penetrating peptides for intracellular delivery of liposomes.
Morten B. Hansen (2012)
Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine.
Wafa’T. Al-Jamal (2011)
Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: an in vivo proof-of-concept study.
M. de Smet (2011)
Nuclear delivery of a therapeutic peptide by long circulating pH-sensitive liposomes: benefits over classical vesicles.
E. Ducat (2011)
The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors
Andrew J Primeau (2005)
Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA
M. Mikhaylova (2009)
In vitro optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein
T. Wang (2011)
Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma.
C. Grange (2010)
pH-responsive polymer-liposomes for intracellular drug delivery and tumor extracellular matrix switched-on targeted cancer therapy.
Yi-Ting Chiang (2014)
Structure-Activity Relationships of Linear and Cyclic Peptides Containing the NGR Tumor-homing Motif*
G. Colombo (2002)
RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer
H. Zhao (2009)
A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma.
H. Hatakeyama (2011)
Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG.
Ling Mei (2014)
Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth
F. Doñate (2008)
Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide
Wendi V. Rodrigueza (2014)
Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes.
S. Malhi (2012)
S. Bharathi (2013)
cRGD-conjugated magnetic-fluorescent liposomes for targeted dual-modality imaging of bone metastasis from prostate cancer
F. Wang (2015)
Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes.
K. Harrington (2001)
Nanocarriers as an emerging platform for cancer therapy.
D. Peer (2007)
IN VITRO RELEASE KINETICS MODEL FITTING OF LIPOSOMES: AN INSIGHT.
Ankit Jain (2016)
The impact of a chlorotoxin-modified liposome system on receptor MMP-2 and the receptor-associated protein ClC-3.
C. Qin (2014)
Reduction-sensitive polymers and bioconjugates for biomedical applications.
F. Meng (2009)
Hyaluronan Polymer Length, Grafting Density, and Surface Poly(ethylene glycol) Coating Influence in Vivo Circulation and Tumor Targeting of Hyaluronan-Grafted Liposomes
H. S. Qhattal (2014)
Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome–DNA complexes
V. Torchilin (2003)
Bioavailability and therapeutic efficacy of HER2 scFv-targeted liposomal doxorubicin in a murine model of HER2-overexpressing breast cancer
Kimberley M Laginha (2008)
State of the art in PEGylation: the great versatility achieved after forty years of research.
G. Pasut (2012)
A novel octreotide modified lipid vesicle improved the anticancer efficacy of doxorubicin in somatostatin receptor 2 positive tumor models.
Junlin Zhang (2010)
A novel DDS strategy, "dual-targeting", and its application for antineovascular therapy.
Yuki Murase (2010)
Cisplatin-alginate conjugate liposomes for targeted delivery to EGFR-positive ovarian cancer cells.
Yunfei Wang (2014)
Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation.
T. Yang (2007)
The use of a tumor metastasis targeting peptide to deliver doxorubicin-containing liposomes to highly metastatic cancer.
Z. Wang (2012)
Ligand-Appended BBB-Targeted Nanocarriers (LABTNs).
Ankit Jain (2015)
Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein.
T. Wang (2010)
Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor.
Sangbin Lee (2012)
Cancer multidrug resistance
A. Persidis (1999)
On the importance of electrostatic interactions between cell penetrating peptides and membranes: a pathway toward tumor cell selectivity?
Marie-Lise Jobin (2014)
The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men
M. Triesscheijn (2006)
Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy.
S. Ran (2002)
Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice
M. S. Newman (1999)
Carbonic anhydrase IX-directed immunoliposomes for targeted drug delivery to human lung cancer cells in vitro
B. C. Wong (2014)
Synthesis and Transfection Activity of New Cationic Phosphoramidate Lipids: High Efficiency of an Imidazolium Derivative
Mathieu Mével (2008)
Enhancement of the uptake and cytotoxic activity of doxorubicin in cancer cells by novel cRGD-semipeptide-anchoring liposomes.
L. Battistini (2014)
Novel multifunctional nanoparticle mediates siRNA tumour delivery, visualisation and therapeutic tumour reduction in vivo.
G. D. Kenny (2011)
Tumor-Targeted Nanomedicines: Enhanced Antitumor Efficacy In vivo of Doxorubicin-Loaded, Long-Circulating Liposomes Modified with Cancer-Specific Monoclonal Antibody
T. Elbayoumi (2009)
Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab′ Fragments
P. Sapra (2004)
Folate and TAT Peptide Co-Modified Liposomes Exhibit Receptor-Dependent Highly Efficient Intracellular Transport of Payload In Vitro and In Vivo
Yaqin Zhu (2014)
Co-Delivery of Doxorubicin and SATB1 shRNA by Thermosensitive Magnetic Cationic Liposomes for Gastric Cancer Therapy
Zhao Peng (2014)
Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
M. Liu (2014)
Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles.
Shyh-Dar Li (2008)
Cancer-Selective Targeting and Cytotoxicity by Liposomal-Coupled Lysosomal Saposin C Protein
X. Qi (2009)
A wogonin-loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects
J. Tian (2014)
Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo.
Y. Obata (2010)
Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes
T. Kikumori (2008)
Epirubicin-encapsulated long-circulating thermosensitive liposome improves pharmacokinetics and antitumor therapeutic efficacy in animals
Y. Wu (2011)
State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines.
Charlene M. Dawidczyk (2014)
P-gp Inhibitors: A Potential Tool to Overcome Drug Resistance in Cancer Chemotherapy
Ankit Jain (2016)
The physics, biophysics and technology of photodynamic therapy.
B. Wilson (2008)
Dual drug delivery using “smart” liposomes for triggered release of anticancer agents
Ankit Jain (2013)
Recent advances with liposomes as pharmaceutical carriers
V. Torchilin (2005)
Dequalinium, a topical antimicrobial agent, displays anticarcinoma activity based on selective mitochondrial accumulation.
M. Weiss (1987)
Nano-aggregates: emerging delivery tools for tumor therapy.
V. K. Sharma (2013)
Relationship of dose intensity to the induction of palmar-plantar erythrodysesthia by pegylated liposomal doxorubicin in dogs
M. Amantea (1999)
PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis.
M. Zigler (2011)
Encapsulation of cisplatin in long-circulating and pH-sensitive liposomes improves its antitumor effect and reduces acute toxicity
E. A. Leite (2012)
Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics.
R. Campbell (2009)
Thioaptamer Conjugated Liposomes for Tumor Vasculature Targeting
A. Mann (2011)
Phototriggering of liposomal drug delivery systems.
P. Shum (2001)
Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo
A. Mori (1991)
Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.
Jean-Sébastien Thomann (2011)
TMTP1, a Novel Tumor-Homing Peptide Specifically Targeting Metastasis
W. Yang (2008)
Enhanced transfection of tumor cells in vivo using “Smart” pH-sensitive TAT-modified pegylated liposomes
A. Kale (2007)
Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Y. Zhang (2010)
In situ dose amplification by apoptosis-targeted drug delivery.
K. Wang (2011)
Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting
P. Ye (2014)
Do folate-receptor targeted liposomal photosensitizers enhance photodynamic therapy selectivity?
M. García-Diaz (2011)
RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis.
F. Danhier (2012)
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.
D. Drummond (2008)
Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes.
Avi Schroeder (2009)
Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity
J. Hu (2008)
Peptide PHSCNK as an integrin α5β1 antagonist targets stealth liposomes to integrin-overexpressing melanoma.
Wenbing Dai (2012)
In vivo near-infrared fluorescence imaging of FAP-expressing tumors with activatable FAP-targeted, single-chain Fv-immunoliposomes.
R. Rüger (2014)
Oncogene dependency and the potential of targeted RNAi-based anti-cancer therapy.
Ruiyang Yan (2014)
Phosphatidylserine-targeted bimodal liposomal nanoparticles for in vivo imaging of breast cancer in mice.
L. Zhang (2014)
Comparative studies of irinotecan-loaded polyethylene glycol-modified liposomes prepared using different PEG-modification methods.
K. Yoshino (2012)
Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects.
K. Maruyama (2011)
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect.
J. Fang (2011)
Ultrasound triggered release of cisplatin from liposomes in murine tumors.
A. Schroeder (2009)
Hyperthermia Sensitization and Proton Beam Triggered Liposomal Drug Release for Targeted Tumor Therapy
R. Fernando (2014)
Tumor–platelet interaction in solid tumors
D. Buergy (2012)
Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent
A. Accardo (2012)
Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides.
I. Nakase (2012)
Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown.
T. Asai (2008)
PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
Y. Yang (2014)
Superhydrophilic zwitterionic polymers stabilize liposomes.
Z. Cao (2012)
Efficacy, Biodistribution, and Pharmacokinetics of CD22-Targeted Pegylated Liposomal Doxorubicin in a B-cell Non–Hodgkin's Lymphoma Xenograft Mouse Model
J. Tuscano (2010)
Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma
Xiaoju Zhou (2012)
Accumulation, internalization and therapeutic efficacy of neuropilin-1-targeted liposomes.
Eric E. Paoli (2014)
A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse
Y. Maitani (2012)
Liposomal drug delivery systems: from concept to clinical applications.
T. Allen (2013)
Liposomes containing NY‑ESO‑1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines.
L. Cruz (2014)
The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats.
T. Ishida (2008)
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.
G. Villares (2008)
Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation.
J. Wenzel (2009)
Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
S. Taurin (2012)
A novel class of photo-triggerable liposomes containing DPPC:DC(8,9)PC as vehicles for delivery of doxorubcin to cells.
Amichai Yavlovich (2011)
Acid-triggered release via dePEGylation of fusogenic liposomes mediated by heterobifunctional phenyl-substituted vinyl ethers with tunable pH-sensitivity.
Hee-Kwon Kim (2012)
Receptor targeted polymers, dendrimers, liposomes: which nanocarrier is the most efficient for tumor-specific treatment and imaging?
M. Saad (2008)
Stimuli-responsive Smart Liposomes in Cancer Targeting.
Ankit Jain (2018)
Liposome imaging agents in personalized medicine.
A. L. Petersen (2012)
Targeting of BRAF resistant melanoma via extracellular matrix metalloproteinase inducer receptor.
Matthew R. Zeiderman (2014)
Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy.
D. Zucker (2012)
Immuno-LipoTRAIL: Targeted delivery of TRAIL-functionalized liposomal nanoparticles.
O. Seifert (2014)
The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals
Y. Men (2011)
Chondroitin sulfate functionalized liposomes for solid tumor targeting
Rashmi Bagari (2011)
Ocular delivery systems for topical application of anti-infective agents
L. Duxfield (2016)
Liposomes and local hyperthermia: selective delivery of methotrexate to heated tumors.
J. Weinstein (1979)
Preparation, characterization, and pharmacodynamics of thermosensitive liposomes containing docetaxel.
H. Zhang (2014)
Tumor-targeting multi-functional nanoparticles for theragnosis: new paradigm for cancer therapy.
Ju Hee Ryu (2012)
Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug.
G. Shim (2011)
The co-delivery of a low-dose P-glycoprotein inhibitor with doxorubicin sterically stabilized liposomes against breast cancer with low P-glycoprotein expression
W. Gao (2014)
Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition.
Alexander Koshkaryev (2013)
Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes.
E. T. Dams (2000)
Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma.
Y. Iwase (2011)
High interstitial fluid pressure — an obstacle in cancer therapy
C. Heldin (2004)
In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination
L. Bonifaz (2004)
Increased delivery of doxorubicin into tumor cells using extracellularly activated TAT functionalized liposomes: in vitro and in vivo study.
W. Yuan (2014)
A novel liposomal vaccine improves humoral immunity and prevents tumor pulmonary metastasis in mice.
Zheng-Hua Zhong (2010)
GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation
Liang Cheng (2014)
Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting.
Lin Zhu (2012)
Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma.
S. Wu (2011)
Theranostic nanoparticles engineered for clinic and pharmaceutics.
Xiaowei Ma (2011)
Bioreducible Liposomes for Gene Delivery: From the Formulation to the Mechanism of Action
G. Candiani (2010)
Targeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studies.
A. Gabizon (1999)
Molecular imaging of angiogenesis to delineate the tumor margins in glioma rat model with endoglin‐targeted paramagnetic liposomes using 3T MRI
Long-Hua Qiu (2015)
Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA.
Shyh-Dar Li (2008)
Targeted siRNA Silencing of Indoleamine 2, 3-Dioxygenase in Antigen-presenting Cells Using Mannose-conjugated Liposomes: A Novel Strategy for Treatment of Melanoma
D. Chen (2014)
Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes.
Rui Kuai (2010)
Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.
Xinyu Wang (2007)
Targeting mitochondria for cancer therapy
S. Fulda (2010)
This paper is referenced by
Advances in liposomal drug delivery to cancer: An overview
Shivani Saraf (2020)
Hyaluronic acid conjugated multi-walled carbon nanotubes for colon cancer targeting.
S. K. Prajapati (2019)
Liposomes for Advanced Drug Delivery
A. Verma (2020)
Emerging potential of niosomes in ocular delivery.
A. Verma (2020)
Folate Conjugated Double Liposomes Bearing Prednisolone and Methotrexate for Targeting Rheumatoid Arthritis
A. Verma (2019)
Engineered liposomes bearing camptothecin analogue for tumor targeting: in vitro and ex-vivo studies.
Shivani Saraf (2020)
Advanced Biopolymeric Systems for Drug Delivery
A. Nayak (2020)
Basics to advances in nanotherapy of colorectal cancer
A. Tiwari (2019)
Sublingual delivery of chondroitin sulfate conjugated tapentadol loaded nanovesicles for the treatment of osteoarthritis.
Mamta Bishnoi (2020)
Ultrasound-based triggered drug delivery to tumors
Ankit Jain (2017)